Answers are grounded in this paper and cite their sources.
We aimed to 1-Estimate costs of the Immune check point inhibitors (ICI), targeted therapy (TT) and other cancer branded trade names 2-Define the conditions and terms of cost legitimacy.A case is being presented to highlight the cost of extended therapy.This 65 yo Caucasian female presented in 2014 with metastatic non-small-cell lung cancer (a/m-NSCLC), ALK +, metastatic to brain, liver, and bone.She was started on Alectinib (Alect) 600 mg po bid.Two weeks later she developed pneumonitis, hospitalized, treated with antibiotics, responded, and discharged.She remained asymptomatic, on Alec.Adverse events (AEs) were constipation and mild lower leg swelling.CT scans revealed marked improvements in liver and brain lesions.Last seen on 1-8-2023, preparing to fly on vacation with husband to Australia.Despite lengthy discussion between patient, husband and oncologists, no decision could be made to stop Alect.Adequately ensured, the patient still pays $700 a month for Alect coverage.Estimated monthly cost was $ 16,570, one year $198,840 and 8-year $1,590,720 [1].
No takes yet. Share an insight, caveat, or question.
H Guirgis (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: